Talk:Oncogenomics

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Genetics task force (assessed as High-importance).
	This article is supported by the Molecular and Cell Biology task force (assessed as High-importance).

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Flowchart

Any chance we could get that in a "vertical" arrangement? I think there would be less wasted white space (or blue space) that way. I have something in mind that does this:

Cancer research box (one arrow down) Oncogenomics box (three arrows down) Improve box - Prognosis box - Therapeutics box

The last three boxes would need their shapes changed (fewer words per line). What do you think? WhatamIdoing (talk) 05:35, 8 March 2008 (UTC)[reply]

Outdated

Content is outdated and inaccurate. — Preceding unsigned comment added by 178.118.91.31 (talk) 02:21, 12 January 2012 (UTC)[reply]

Tumor evolution clarification

Second paragraph reads: "Cancer develops due to DNA mutations and epigenetic alterations that accumulate randomly. Identifying and targeting the mutations in an individual patient may lead to increased treatment efficacy."

Genetic mutations are generated randomly but they do not accumulate randomly. Like any biological self-replicating entity, tumors are subject to selective pressures like metabolic limitations, chemotherapeutics, and immune surveillance. Genetic mutations accumulate non-randomly because of selection pressures. Cells with advantages (e.g. chemo efflux pumps) are more likely to be selected and the gene or genes responsible for the efflux pump increase in frequency non-randomly. I think this is an important point because targeted therapies are aimed at these advantages.